Pfizer’s antiviral covid pill is almost 90% effective, also works on Omicron variant

 

In the final analysis of Pfizer’s antiviral covid pill, it showed nearly 90% efficiency in preventing deaths and hospitalizations compared to placebo, based on the meantime results in 1,200 people. 

 

Pfizer is an American Multinational Pharmaceutical company and drugmaker headquartered in Manhattan, Newyork City. Pfizer is a pioneer in the development of covid vaccines.

 

Pfizer Inc said their lab data indicate that their novel drug keep hold of the effectiveness against the Omicron variant of coronavirus.

They unfolded their data reports on Tuesday, December 14th including additional data of 1,000 people.

 

“It’s a stunning outcome,” Pfizer Chief Scientific Officer Mikael Dolsten said.”We’re talking about a staggering number of lives saved and hospitalizations prevented. And of course, if you deploy this quickly after infection, we are likely to reduce transmission dramatically.”

 

Pfizer’s drug is a part of a drug group called protease inhibitors, which are synthetic drugs that hinder the actions of HIV, hepatitis-C, and other viruses.

 

Covid pill by pfizer showed 90% effective
Covid pill by Pfizer showed 90% effective

 

These new Pfizer pills are taken every 12 hours with the previous antiviral ritonavir for five days.

 The pill intake must be done at the beginning onset of covid symptoms. 

 

If the new treatment is authorized, it will be sold as the same done for Paxlovid, an antiviral drug developed by Pfizer for covid.

 

Then, Pfizer published a second clinical trial report that shows the treatment diminished hospitalizations by 70%. 

 

This was such a great achievement. Pfizer will continue their trial and more data can be expected soon. 

 

According to Dolsten, this pill can be used in high-risk individuals after they get authorization from US Food and Drug Administration and other regulatory agencies. 

 

He says he does not believe an FDA advisory panel meeting will be needed.

 

“It’s a stunning outcome,” Pfizer Chief Scientific Officer Mikael Dolsten said in an interview.

“We’re in very advanced regulatory dialogues with both Europe and the UK, and we have dialogues with most of the major regulatory agencies globally,” Dolsten said.

 

However, Pfizer submitted their report to the US FDA last month. They hope they shall get emergency use authorization. The FDA’s decision will come within weeks.

According to Dolsten, Pfizer might be able to produce the drug massively by next year and we might keep corona variants in check.

 

Next video: Researchers hope to find a Cure for HIV by 2030, trials on humans start Next year